All press releases
-
Evexta Bio Appoints Edith A. Perez as Scientific Advisor
-
Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors
-
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
-
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
-
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
-
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany
-
Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy